checkAd

     134  0 Kommentare Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19 - Seite 3

    Contacts:

    Lesen Sie auch

    Mark Flather
    Senior Director, Investor Relations
    & Corporate Communications
    Adamis Pharmaceuticals Corporation
    (858) 412-7951
    mflather@adamispharma.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19 - Seite 3 SAN DIEGO, Aug. 14, 2020 (GLOBE NEWSWIRE) - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), the …